These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2483466)

  • 1. [Interstitial pneumonia in bone marrow transplantation. Preventive and therapeutic aspects. Our experience and review of the literature].
    Zabala P; Campano F; Candela MJ; Regidor C; Cabrera R; Sanjuán I; Barbolla L; Fernández MN
    Sangre (Barc); 1989 Dec; 34(6):489-96. PubMed ID: 2483466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
    von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
    Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
    Funada H; Harada M; Yoshida T; Hattori K
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.
    Schmidt GM; Kovacs A; Zaia JA; Horak DA; Blume KG; Nademanee AP; O'Donnell MR; Snyder DS; Forman SJ
    Transplantation; 1988 Dec; 46(6):905-7. PubMed ID: 2849818
    [No Abstract]   [Full Text] [Related]  

  • 8. Prophylaxis and treatment of infection in the bone marrow transplant recipient.
    Winston DJ
    Curr Clin Top Infect Dis; 1993; 13():293-321. PubMed ID: 8397916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pattern of interstitial pneumonitis following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989.
    Atkinson K; Nivison-Smith I; Dodds A; Concannon A; Milliken S; Downs K
    Bone Marrow Transplant; 1998 Apr; 21(7):691-5. PubMed ID: 9578309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
    Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
    Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
    J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Infectious Disease Working Party of the European Group for Bone Marrow Transplantation.
    Ljungman P; Biron P; Bosi A; Cahn JY; Goldstone AH; Gorin NC; Link H; Messina C; Michallet M; Richard C
    Bone Marrow Transplant; 1994 Feb; 13(2):209-12. PubMed ID: 8205091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
    Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
    Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis of infection in bone marrow transplants.
    Winston DJ; Ho WG; Gale RP; Champlin RE
    Eur J Cancer Clin Oncol; 1988; 24 Suppl 1():S15-23. PubMed ID: 3127217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir.
    Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
    Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation.
    Jacobsen N; Schäfer U; Ostendorf P; Kubaneck B; Wolf H
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):193-5. PubMed ID: 3010510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganciclovir and standard high-dose immunoglobulins for the treatment of cytomegalovirus interstitial pneumonia in a bone marrow recipient.
    Iori AP; Gentile G; Petasecca Donati P; Arcese W; Martino P; Mandelli F
    Haematologica; 1990; 75(4):394-6. PubMed ID: 2177441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.